Android app on Google Play

Needham & Company Discusses Vertex (VRTX) Phase 2 Trial of Ivacaftor in CF

June 4, 2014 10:08 AM EDT Send to a Friend
Get Alerts VRTX Hot Sheet
Price: $104.71 +0.93%

Rating Summary:
    19 Buy, 13 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 25 | New: 14
Trade VRTX Now!
Join SI Premium – FREE

Needham & Company analyst Alan Carr weighed in on Vertex (NASDAQ: VRTX) following top-line results from a Phase 2 trial of ivacaftor in cystic fibrosis patients with residual function CFTR mutations.

"We note statistically significant, but modest absolute changes in FEV1 in the two-part trial (2.8% vs. 0.6% placebo [p=0.004] in 2-wk blinded Part 1 and 4.7% [p=0.0001] in 8-wk open-label Part 2)," Carr said. "Based on these results, the company plans to move forward with a Phase 3 trial after discussions with regulators around trial design. Results from the pivotal TRAFFIC and TRANSPORT trials are expected soon. These trials are testing ivacaftor/lumacaftor in homozygous F508del pts and are at the core of the company's CF strategy. We continue to expect a positive outcome and reiterate our BUY rating and $95 target."

For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.

Shares of Vertex closed at $72.96 yesterday.





You May Also Be Interested In


Related Categories

Analyst Comments, FDA

Related Entities

Needham & Company

Add Your Comment